ID   S20A2_HUMAN             Reviewed;         652 AA.
AC   Q08357;
DT   10-JUN-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   10-MAY-2017, entry version 135.
DE   RecName: Full=Sodium-dependent phosphate transporter 2;
DE   AltName: Full=Gibbon ape leukemia virus receptor 2;
DE            Short=GLVR-2;
DE   AltName: Full=Phosphate transporter 2;
DE            Short=PiT-2;
DE            Short=Pit2;
DE            Short=hPit2;
DE   AltName: Full=Solute carrier family 20 member 2;
GN   Name=SLC20A2; Synonyms=GLVR2, PIT2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION AS RETROVIRAL RECEPTOR.
RC   TISSUE=Placenta;
RX   PubMed=8302848; DOI=10.1073/pnas.91.3.1168;
RA   van Zeijl M., Johann S.V., Closs E., Cunningham J., Eddy R.,
RA   Shows T.B., O'Hara B.;
RT   "A human amphotropic retrovirus receptor is a second member of the
RT   gibbon ape leukemia virus receptor family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:1168-1172(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   TOPOLOGY, GLYCOSYLATION AT ASN-81, AND MUTAGENESIS OF ASN-81.
RX   PubMed=11356966; DOI=10.1128/JVI.75.12.5584-5592.2001;
RA   Salauen C., Rodrigues P., Heard J.M.;
RT   "Transmembrane topology of PiT-2, a phosphate transporter-retrovirus
RT   receptor.";
RL   J. Virol. 75:5584-5592(2001).
RN   [5]
RP   TOPOLOGY, SUBCELLULAR LOCATION, AND INDUCTION.
RX   PubMed=9151850;
RA   Chien M.L., Foster J.L., Douglas J.L., Garcia J.V.;
RT   "The amphotropic murine leukemia virus receptor gene encodes a 71-
RT   kilodalton protein that is induced by phosphate depletion.";
RL   J. Virol. 71:4564-4570(1997).
RN   [6]
RP   FUNCTION AS RETROVIRAL RECEPTOR.
RX   PubMed=11435563; DOI=10.1128/JVI.75.15.6841-6849.2001;
RA   Sugai J., Eiden M., Anderson M.M., Van Hoeven N., Meiering C.D.,
RA   Overbaugh J.;
RT   "Identification of envelope determinants of feline leukemia virus
RT   subgroup B that permit infection and gene transfer to cells expressing
RT   human Pit1 or Pit2.";
RL   J. Virol. 75:6841-6849(2001).
RN   [7]
RP   FUNCTION AS SODIUM-PHOSPHATE SYMPORTER, SUBUNIT, AND MUTAGENESIS OF
RP   GLU-55 AND GLU-575.
RX   PubMed=12205090; DOI=10.1074/jbc.M207096200;
RA   Boettger P., Pedersen L.;
RT   "Two highly conserved glutamate residues critical for type III sodium-
RT   dependent phosphate transport revealed by uncoupling transport
RT   function from retroviral receptor function.";
RL   J. Biol. Chem. 277:42741-42747(2002).
RN   [8]
RP   FUNCTION AS SODIUM-PHOSPHATE SYMPORTER, SUBUNIT, MUTAGENESIS OF
RP   ASP-506, AND CHARACTERIZATION OF VARIANT IBGC1 ASN-28.
RX   PubMed=15955065; DOI=10.1111/j.1742-4658.2005.04720.x;
RA   Boettger P., Pedersen L.;
RT   "Evolutionary and experimental analyses of inorganic phosphate
RT   transporter PiT family reveals two related signature sequences
RT   harboring highly conserved aspartic acids critical for sodium-
RT   dependent phosphate transport function of human PiT2.";
RL   FEBS J. 272:3060-3074(2005).
RN   [9]
RP   FUNCTION AS SODIUM-PHOSPHATE SYMPORTER, BIOPHYSICOCHEMICAL PROPERTIES,
RP   AND MUTAGENESIS OF GLU-55; GLU-91 AND GLU-575.
RX   PubMed=16790504; DOI=10.1152/ajpcell.00015.2006;
RA   Boettger P., Hede S.E., Grunnet M., Hoyer B., Klaerke D.A.,
RA   Pedersen L.;
RT   "Characterization of transport mechanisms and determinants critical
RT   for Na+-dependent Pi symport of the PiT family paralogs human PiT1 and
RT   PiT2.";
RL   Am. J. Physiol. 291:C1377-C1387(2006).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-268, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-256; SER-259; SER-268;
RP   SER-316 AND SER-385, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-259 AND SER-316, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   VARIANTS IBGC1 VAL-42 DEL; ARG-498; LYS-575; MET-595; TRP-601 AND
RP   LEU-601, AND CHARACTERIZATION OF VARIANTS IBGC1 VAL-42 DEL; ARG-498;
RP   LYS-575; MET-595; TRP-601 AND LEU-601.
RX   PubMed=22327515; DOI=10.1038/ng.1077;
RA   Wang C., Li Y., Shi L., Ren J., Patti M., Wang T., de Oliveira J.R.,
RA   Sobrido M.J., Quintans B., Baquero M., Cui X., Zhang X.Y., Wang L.,
RA   Xu H., Wang J., Yao J., Dai X., Liu J., Zhang L., Ma H., Gao Y.,
RA   Ma X., Feng S., Liu M., Wang Q.K., Forster I.C., Zhang X., Liu J.Y.;
RT   "Mutations in SLC20A2 link familial idiopathic basal ganglia
RT   calcification with phosphate homeostasis.";
RL   Nat. Genet. 44:254-256(2012).
RN   [15]
RP   INVOLVEMENT IN IBGC1.
RX   PubMed=23406454; DOI=10.1111/ene.12044;
RA   Lemos R.R., Oliveira M.F., Oliveira J.R.;
RT   "Reporting a new mutation at the SLC20A2 gene in familial idiopathic
RT   basal ganglia calcification.";
RL   Eur. J. Neurol. 20:E43-43(2013).
RN   [16]
RP   VARIANTS IBGC1 LEU-11; ASN-28 AND PRO-62.
RX   PubMed=23939468; DOI=10.1016/j.gene.2013.07.071;
RA   Chen W.J., Yao X.P., Zhang Q.J., Ni W., He J., Li H.F., Liu X.Y.,
RA   Zhao G.X., Murong S.X., Wang N., Wu Z.Y.;
RT   "Novel SLC20A2 mutations identified in southern Chinese patients with
RT   idiopathic basal ganglia calcification.";
RL   Gene 529:159-162(2013).
RN   [17]
RP   VARIANTS IBGC1 GLN-382; GLN-502; LEU-568 AND LEU-601.
RX   PubMed=23334463; DOI=10.1007/s10048-012-0349-2;
RA   Hsu S.C., Sears R.L., Lemos R.R., Quintans B., Huang A., Spiteri E.,
RA   Nevarez L., Mamah C., Zatz M., Pierce K.D., Fullerton J.M.,
RA   Adair J.C., Berner J.E., Bower M., Brodaty H., Carmona O.,
RA   Dobricic V., Fogel B.L., Garcia-Estevez D., Goldman J., Goudreau J.L.,
RA   Hopfer S., Jankovic M., Jauma S., Jen J.C., Kirdlarp S., Klepper J.,
RA   Kostic V., Lang A.E., Linglart A., Maisenbacher M.K., Manyam B.V.,
RA   Mazzoni P., Miedzybrodzka Z., Mitarnun W., Mitchell P.B., Mueller J.,
RA   Novakovic I., Paucar M., Paulson H., Simpson S.A., Svenningsson P.,
RA   Tuite P., Vitek J., Wetchaphanphesat S., Williams C., Yang M.,
RA   Schofield P.R., de Oliveira J.R., Sobrido M.J., Geschwind D.H.,
RA   Coppola G.;
RT   "Mutations in SLC20A2 are a major cause of familial idiopathic basal
RT   ganglia calcification.";
RL   Neurogenetics 14:11-22(2013).
RN   [18]
RP   VARIANTS IBGC1 ASN-28; LEU-184; SER-194 AND SER-571.
RX   PubMed=24065723; DOI=10.1093/brain/awt255;
RG   French IBGC Study Group;
RA   Nicolas G., Pottier C., Charbonnier C., Guyant-Marechal L., Le Ber I.,
RA   Pariente J., Labauge P., Ayrignac X., Defebvre L., Maltete D.,
RA   Martinaud O., Lefaucheur R., Guillin O., Wallon D., Chaumette B.,
RA   Rondepierre P., Derache N., Fromager G., Schaeffer S., Krystkowiak P.,
RA   Verny C., Jurici S., Sauvee M., Verin M., Lebouvier T., Rouaud O.,
RA   Thauvin-Robinet C., Rousseau S., Rovelet-Lecrux A., Frebourg T.,
RA   Campion D., Hannequin D.;
RT   "Phenotypic spectrum of probable and genetically-confirmed idiopathic
RT   basal ganglia calcification.";
RL   Brain 136:3395-3407(2013).
RN   [19]
RP   VARIANTS IBGC1 TRP-434 AND MET-595.
RX   PubMed=25284758; DOI=10.1002/mds.26053;
RA   Taglia I., Mignarri A., Olgiati S., Menci E., Petrocelli P.L.,
RA   Breedveld G.J., Scaglione C., Martinelli P., Federico A., Bonifati V.,
RA   Dotti M.T.;
RT   "Primary familial brain calcification: Genetic analysis and clinical
RT   spectrum.";
RL   Mov. Disord. 29:1691-1695(2014).
RN   [20]
RP   VARIANTS IBGC1 VAL-51; HIS-71; MET-115 AND ARG-637.
RX   PubMed=24463626; DOI=10.1212/WNL.0000000000000143;
RA   Yamada M., Tanaka M., Takagi M., Kobayashi S., Taguchi Y.,
RA   Takashima S., Tanaka K., Touge T., Hatsuta H., Murayama S.,
RA   Hayashi Y., Kaneko M., Ishiura H., Mitsui J., Atsuta N., Sobue G.,
RA   Shimozawa N., Inuzuka T., Tsuji S., Hozumi I.;
RT   "Evaluation of SLC20A2 mutations that cause idiopathic basal ganglia
RT   calcification in Japan.";
RL   Neurology 82:705-712(2014).
CC   -!- FUNCTION: Sodium-phosphate symporter which seems to play a
CC       fundamental housekeeping role in phosphate transport by absorbing
CC       phosphate from interstitial fluid for normal cellular functions
CC       such as cellular metabolism, signal transduction, and nucleic acid
CC       and lipid synthesis. In vitro, sodium-dependent phosphate uptake
CC       is not siginificantly affected by acidic and alkaline conditions,
CC       however sodium-independent phosphate uptake occurs at acidic
CC       conditions. May play a role in extracellular matrix, cartilage and
CC       vascular calcification. Functions as a retroviral receptor and
CC       confers human cells susceptibility to infection to amphotropic
CC       murine leukemia virus (A-MuLV), 10A1 murine leukemia virus (10A1
CC       MLV) and some feline leukemia virus subgroup B (FeLV-B) variants.
CC       {ECO:0000269|PubMed:11435563, ECO:0000269|PubMed:12205090,
CC       ECO:0000269|PubMed:15955065, ECO:0000269|PubMed:16790504,
CC       ECO:0000269|PubMed:8302848}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:12205090,
CC       ECO:0000269|PubMed:15955065}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:9151850};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:9151850}.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed.
CC   -!- INDUCTION: Increased by phosphate depletion in osteosarcoma cell
CC       lines. {ECO:0000269|PubMed:9151850}.
CC   -!- DISEASE: Basal ganglia calcification, idiopathic, 1 (IBGC1)
CC       [MIM:213600]: A form of basal ganglia calcification, an autosomal
CC       dominant condition characterized by symmetric calcification in the
CC       basal ganglia and other brain regions. Affected individuals can
CC       either be asymptomatic or show a wide spectrum of neuropsychiatric
CC       symptoms, including parkinsonism, dystonia, tremor, ataxia,
CC       dementia, psychosis, seizures, and chronic headache. Serum levels
CC       of calcium, phosphate, alkaline phosphatase and parathyroid
CC       hormone are normal. The neuropathological hallmark of the disease
CC       is vascular and pericapillary calcification, mainly of calcium
CC       phosphate, in the affected brain areas.
CC       {ECO:0000269|PubMed:15955065, ECO:0000269|PubMed:22327515,
CC       ECO:0000269|PubMed:23334463, ECO:0000269|PubMed:23406454,
CC       ECO:0000269|PubMed:23939468, ECO:0000269|PubMed:24065723,
CC       ECO:0000269|PubMed:24463626, ECO:0000269|PubMed:25284758}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the inorganic phosphate transporter (PiT)
CC       (TC 2.A.20) family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L20852; AAA18018.1; -; mRNA.
DR   EMBL; AK291202; BAF83891.1; -; mRNA.
DR   EMBL; BC028600; AAH28600.1; -; mRNA.
DR   CCDS; CCDS6132.1; -.
DR   PIR; A37000; A37000.
DR   RefSeq; NP_001244109.1; NM_001257180.1.
DR   RefSeq; NP_001244110.1; NM_001257181.1.
DR   RefSeq; NP_006740.1; NM_006749.4.
DR   RefSeq; XP_005273670.1; XM_005273613.3.
DR   RefSeq; XP_016869237.1; XM_017013748.1.
DR   UniGene; Hs.653173; -.
DR   UniGene; Hs.654763; -.
DR   ProteinModelPortal; Q08357; -.
DR   BioGrid; 112463; 13.
DR   IntAct; Q08357; 2.
DR   STRING; 9606.ENSP00000340465; -.
DR   TCDB; 2.A.20.2.3; the inorganic phosphate transporter (pit) family.
DR   iPTMnet; Q08357; -.
DR   PhosphoSitePlus; Q08357; -.
DR   BioMuta; SLC20A2; -.
DR   DMDM; 74735615; -.
DR   EPD; Q08357; -.
DR   MaxQB; Q08357; -.
DR   PaxDb; Q08357; -.
DR   PeptideAtlas; Q08357; -.
DR   PRIDE; Q08357; -.
DR   DNASU; 6575; -.
DR   Ensembl; ENST00000342228; ENSP00000340465; ENSG00000168575.
DR   Ensembl; ENST00000520179; ENSP00000429712; ENSG00000168575.
DR   Ensembl; ENST00000520262; ENSP00000429754; ENSG00000168575.
DR   GeneID; 6575; -.
DR   KEGG; hsa:6575; -.
DR   UCSC; uc003xpe.5; human.
DR   CTD; 6575; -.
DR   DisGeNET; 6575; -.
DR   GeneCards; SLC20A2; -.
DR   GeneReviews; SLC20A2; -.
DR   HGNC; HGNC:10947; SLC20A2.
DR   HPA; HPA026540; -.
DR   MalaCards; SLC20A2; -.
DR   MIM; 158378; gene.
DR   MIM; 213600; phenotype.
DR   neXtProt; NX_Q08357; -.
DR   OpenTargets; ENSG00000168575; -.
DR   Orphanet; 1980; Bilateral striopallidodentate calcinosis.
DR   PharmGKB; PA35834; -.
DR   eggNOG; KOG2493; Eukaryota.
DR   eggNOG; COG0306; LUCA.
DR   GeneTree; ENSGT00390000014879; -.
DR   HOGENOM; HOG000231892; -.
DR   HOVERGEN; HBG053358; -.
DR   InParanoid; Q08357; -.
DR   KO; K14640; -.
DR   OMA; PAQESNY; -.
DR   OrthoDB; EOG091G07J5; -.
DR   PhylomeDB; Q08357; -.
DR   TreeFam; TF314426; -.
DR   Reactome; R-HSA-427652; Sodium-coupled phosphate cotransporters.
DR   ChiTaRS; SLC20A2; human.
DR   GeneWiki; SLC20A2; -.
DR   GenomeRNAi; 6575; -.
DR   PRO; PR:Q08357; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000168575; -.
DR   CleanEx; HS_SLC20A2; -.
DR   ExpressionAtlas; Q08357; baseline and differential.
DR   Genevisible; Q08357; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005315; F:inorganic phosphate transmembrane transporter activity; IEA:InterPro.
DR   GO; GO:0004872; F:receptor activity; TAS:ProtInc.
DR   GO; GO:0015321; F:sodium-dependent phosphate transmembrane transporter activity; TAS:Reactome.
DR   GO; GO:0005436; F:sodium:phosphate symporter activity; TAS:ProtInc.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0006811; P:ion transport; TAS:Reactome.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   InterPro; IPR001204; Phos_transporter.
DR   PANTHER; PTHR11101; PTHR11101; 1.
DR   Pfam; PF01384; PHO4; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disease mutation; Glycoprotein;
KW   Host cell receptor for virus entry; Host-virus interaction;
KW   Ion transport; Membrane; Phosphate transport; Phosphoprotein;
KW   Receptor; Reference proteome; Sodium; Sodium transport; Symport;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN         1    652       Sodium-dependent phosphate transporter 2.
FT                                /FTId=PRO_0000341268.
FT   TOPO_DOM      1      5       Extracellular. {ECO:0000255}.
FT   TRANSMEM      6     26       Helical. {ECO:0000255}.
FT   TOPO_DOM     27     46       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     47     67       Helical. {ECO:0000255}.
FT   TOPO_DOM     68     86       Extracellular. {ECO:0000255}.
FT   TRANSMEM     87    107       Helical. {ECO:0000255}.
FT   TOPO_DOM    108    109       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    110    130       Helical. {ECO:0000255}.
FT   TOPO_DOM    131    142       Extracellular. {ECO:0000255}.
FT   TRANSMEM    143    163       Helical. {ECO:0000255}.
FT   TOPO_DOM    164    190       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    191    211       Helical. {ECO:0000255}.
FT   TOPO_DOM    212    213       Extracellular. {ECO:0000255}.
FT   TRANSMEM    214    234       Helical. {ECO:0000255}.
FT   TOPO_DOM    235    482       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    483    503       Helical. {ECO:0000255}.
FT   TOPO_DOM    504    530       Extracellular. {ECO:0000255}.
FT   TRANSMEM    531    551       Helical. {ECO:0000255}.
FT   TOPO_DOM    552    571       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    572    586       Helical. {ECO:0000255}.
FT   TOPO_DOM    587    593       Extracellular. {ECO:0000255}.
FT   TRANSMEM    594    609       Helical. {ECO:0000255}.
FT   TOPO_DOM    610    621       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    622    642       Helical. {ECO:0000255}.
FT   TOPO_DOM    643    652       Extracellular. {ECO:0000255}.
FT   MOD_RES     253    253       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63488}.
FT   MOD_RES     256    256       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     259    259       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     268    268       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     316    316       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     385    385       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CARBOHYD     81     81       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:11356966}.
FT   VARIANT      11     11       I -> L (in IBGC1; dbSNP:rs201836672).
FT                                {ECO:0000269|PubMed:23939468}.
FT                                /FTId=VAR_072255.
FT   VARIANT      28     28       D -> N (in IBGC1; Impairs phosphate
FT                                transport; no effect on retroviral
FT                                receptor function).
FT                                {ECO:0000269|PubMed:15955065,
FT                                ECO:0000269|PubMed:23939468,
FT                                ECO:0000269|PubMed:24065723}.
FT                                /FTId=VAR_072256.
FT   VARIANT      42     42       Missing (in IBGC1; substantially impaired
FT                                phosphate transport).
FT                                {ECO:0000269|PubMed:22327515}.
FT                                /FTId=VAR_067545.
FT   VARIANT      51     51       A -> V (in IBGC1).
FT                                {ECO:0000269|PubMed:24463626}.
FT                                /FTId=VAR_072257.
FT   VARIANT      62     62       L -> P (in IBGC1).
FT                                {ECO:0000269|PubMed:23939468}.
FT                                /FTId=VAR_072258.
FT   VARIANT      71     71       R -> H (in IBGC1).
FT                                {ECO:0000269|PubMed:24463626}.
FT                                /FTId=VAR_072259.
FT   VARIANT     115    115       T -> M (in IBGC1; dbSNP:rs775911275).
FT                                {ECO:0000269|PubMed:24463626}.
FT                                /FTId=VAR_072260.
FT   VARIANT     184    184       P -> L (in IBGC1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:24065723}.
FT                                /FTId=VAR_075396.
FT   VARIANT     194    194       N -> S (in IBGC1; unknown pathological
FT                                significance; dbSNP:rs748252183).
FT                                {ECO:0000269|PubMed:24065723}.
FT                                /FTId=VAR_075397.
FT   VARIANT     382    382       R -> Q (in IBGC1; dbSNP:rs200010919).
FT                                {ECO:0000269|PubMed:23334463}.
FT                                /FTId=VAR_072261.
FT   VARIANT     434    434       S -> W (in IBGC1).
FT                                {ECO:0000269|PubMed:25284758}.
FT                                /FTId=VAR_072262.
FT   VARIANT     498    498       G -> R (in IBGC1; substantially impaired
FT                                phosphate transport).
FT                                {ECO:0000269|PubMed:22327515}.
FT                                /FTId=VAR_067546.
FT   VARIANT     502    502       H -> Q (in IBGC1).
FT                                {ECO:0000269|PubMed:23334463}.
FT                                /FTId=VAR_072263.
FT   VARIANT     568    568       P -> L (in IBGC1; dbSNP:rs763252801).
FT                                {ECO:0000269|PubMed:23334463}.
FT                                /FTId=VAR_072264.
FT   VARIANT     571    571       G -> S (in IBGC1).
FT                                {ECO:0000269|PubMed:24065723}.
FT                                /FTId=VAR_075398.
FT   VARIANT     575    575       E -> K (in IBGC1; substantially impaired
FT                                phosphate transport; dbSNP:rs387906653).
FT                                {ECO:0000269|PubMed:22327515}.
FT                                /FTId=VAR_067547.
FT   VARIANT     595    595       T -> M (in IBGC1; substantially impaired
FT                                phosphate transport; dbSNP:rs387906654).
FT                                {ECO:0000269|PubMed:22327515,
FT                                ECO:0000269|PubMed:25284758}.
FT                                /FTId=VAR_067548.
FT   VARIANT     601    601       S -> L (in IBGC1; substantially impaired
FT                                phosphate transport; dbSNP:rs387906652).
FT                                {ECO:0000269|PubMed:22327515,
FT                                ECO:0000269|PubMed:23334463}.
FT                                /FTId=VAR_067549.
FT   VARIANT     601    601       S -> W (in IBGC1; substantially impaired
FT                                phosphate transport; dbSNP:rs387906652).
FT                                {ECO:0000269|PubMed:22327515}.
FT                                /FTId=VAR_067550.
FT   VARIANT     637    637       S -> R (in IBGC1).
FT                                {ECO:0000269|PubMed:24463626}.
FT                                /FTId=VAR_072265.
FT   MUTAGEN      55     55       E->D,K: Abolishes sodium-dependent
FT                                phosphate transport; no effect on
FT                                retroviral receptor function.
FT                                {ECO:0000269|PubMed:12205090,
FT                                ECO:0000269|PubMed:16790504}.
FT   MUTAGEN      55     55       E->Q: Abolishes phosphate but not sodium
FT                                uptake; when associated with Q-91 and Q-
FT                                575. {ECO:0000269|PubMed:12205090,
FT                                ECO:0000269|PubMed:16790504}.
FT   MUTAGEN      81     81       N->V: Abolishes N-glycosylation.
FT                                {ECO:0000269|PubMed:11356966}.
FT   MUTAGEN      91     91       E->Q: Abolishes phosphate but not sodium
FT                                uptake; when associated with Q-55 and Q-
FT                                575. {ECO:0000269|PubMed:16790504}.
FT   MUTAGEN     506    506       D->N: Impairs phosphate transport; no
FT                                effect on retroviral receptor function.
FT                                {ECO:0000269|PubMed:15955065}.
FT   MUTAGEN     575    575       E->D,K: Abolishes sodium-dependent
FT                                phosphate transport; no effect on
FT                                retroviral receptor function.
FT                                {ECO:0000269|PubMed:12205090,
FT                                ECO:0000269|PubMed:16790504}.
FT   MUTAGEN     575    575       E->Q: Abolishes phosphate but not sodium
FT                                uptake; when associated with Q-55 and Q-
FT                                91. {ECO:0000269|PubMed:12205090,
FT                                ECO:0000269|PubMed:16790504}.
SQ   SEQUENCE   652 AA;  70392 MW;  A0A870C7927DE39C CRC64;
     MAMDEYLWMV ILGFIIAFIL AFSVGANDVA NSFGTAVGSG VVTLRQACIL ASIFETTGSV
     LLGAKVGETI RKGIIDVNLY NETVETLMAG EVSAMVGSAV WQLIASFLRL PISGTHCIVG
     STIGFSLVAI GTKGVQWMEL VKIVASWFIS PLLSGFMSGL LFVLIRIFIL KKEDPVPNGL
     RALPVFYAAT IAINVFSIMY TGAPVLGLVL PMWAIALISF GVALLFAFFV WLFVCPWMRR
     KITGKLQKEG ALSRVSDESL SKVQEAESPV FKELPGAKAN DDSTIPLTGA AGETLGTSEG
     TSAGSHPRAA YGRALSMTHG SVKSPISNGT FGFDGHTRSD GHVYHTVHKD SGLYKDLLHK
     IHIDRGPEEK PAQESNYRLL RRNNSYTCYT AAICGLPVHA TFRAADSSAP EDSEKLVGDT
     VSYSKKRLRY DSYSSYCNAV AEAEIEAEEG GVEMKLASEL ADPDQPREDP AEEEKEEKDA
     PEVHLLFHFL QVLTACFGSF AHGGNDVSNA IGPLVALWLI YKQGGVTQEA ATPVWLLFYG
     GVGICTGLWV WGRRVIQTMG KDLTPITPSS GFTIELASAF TVVIASNIGL PVSTTHCKVG
     SVVAVGWIRS RKAVDWRLFR NIFVAWFVTV PVAGLFSAAV MALLMYGILP YV
//
